Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic

May 30, 2017

SAN DIEGO, May 30, 2017 /PRNewswire/ — Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that it has entered into a research agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation in which CFFT will pay up to […]

Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)

December 6, 2016

San Diego, Calif., Dec 6, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA- based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus’ wholly-owned therapeutic delivery platform LUNARTM and […]

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

October 29, 2015

NOVATO, CA – October 29, 2015 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA […]